Investigator ratings of ADHD symptoms during a randomized, placebo-controlled trial of atomoxetine: a comparison of parents and teachers as informants.
This study compared investigator ratings of ADHD symptoms based on interviews with parents and teachers during a doubleblind, placebo-controlled study of atomoxetine. Investigators completed the ADHD Rating Scale: Investigator (ADHDRS-I) based on separate semistructured interviews with the primary caretaker and teacher of the participant. Interviews were conducted at Visits 2 to 7 during a double-blind treatment protocol comparing atomoxetine (N= 10) and placebo (N= 6). Both parent and teacher-based ratings were sensitive to change in ADHD symptoms with atomoxetine treatment. Parent-based assessment differentiated significantly between treatment with atomoxetine and placebo, whereas teacher-based assessment was less sensitive to change. Parents and teachers showed good agreement on change in ADHDRS-I scores. Investigator ratings based on parent- and teacher-report were sensitive to change in symptoms of ADHD during treatment with atomoxetine. Despite good agreement between parent- and teacher-based ratings of symptom change, parent-based ADHD symptom ratings are more sensitive to symptom change.
Bohnstedt
Bradley N
BN
Indiana University School of Medicine, Indianapolis, Indiana 46202, USA.
Kronenberger
William G
WG
Dunn
David W
DW
Giauque
Ann L
AL
Wood
Elisabeth A
EA
Rembusch
Mary E
ME
Lafata
Deborah
D
D000069445:Atomoxetine Hydrochloride; D001289:Attention Deficit Disorder with Hyperactivity / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology*; D002648:Child; D004311:Double-Blind Method; D005178:Faculty; D005260:Female; D006801:Humans; D008297:Male; D009638:Norepinephrine / Q000037:antagonists & inhibitors; D015588:Observer Variation; D010290:Parents; D011437:Propylamines / Q000494:pharmacology / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales
D011437:Propylamines; D000069445:Atomoxetine Hydrochloride; D009638:Norepinephrine